This product listing is for 4 vials, 5mg each, total: 20mg
GHRP-2 (growth hormone releasing peptide 2) is a growth hormone secretagogue and synthetic hexapeptide analog of ghrelin. Like ghrelin, GHRP-2 induces endogenous growth hormone (GH) release from the pituitary by inhibiting somatostatin. As ghrelin is synergistic with endogenous growth hormone releasing hormone (GHRH), GHRP-2 is synergistic with synthetic GHRH analogs such as Modified GRF (1-29). Compared to rHGH, growth hormone secretagogues are cheaper, easier to manufacture, and may be equally or more effective with fewer side-effects, representing an attractive development candidate. Compared to other ghrelin analogs, GHRP-2 is generally more potent with more selectivity for GH release.
GHRP-2 increases the number of active or participating pituitary somatotrophs (specialized cells that produce, store, and release GH), whereas GHRH and its analogs increase the pulse amplitude of participating cells. Combined in a simultaneous application, the two peptides release significantly more GH than the combined total release of each peptide used individually.
GHRP-2 is a hexapeptide, as opposed to 28-amino-acid full-chain ghrelin; also unlike ghrelin, GHRP-2 is not lipogenic (fat-storing); and while ghrelin has a very important role in hunger, GHRP-2 as an analog of ghrelin does not increase appetite significantly.
Pituitary neuroendocrine excitation lasts for approximately one hour after GHRP-2 dosing, causing a rapid high-amplitude pulsatile release of GH and tapering back to baseline by the third hour after application. This pulse mimics normal endogenous GH release, except with a higher amplitude. In human trials, a dose of 1mcg/kg (100mg for a 100kg male) of GHRP-2 combined with a GHRH in equal dosage induces a three-hour pulse of GH at double the amplitude of an 8 IU synthetic rHGH dose.
Compared to rHGH therapy, GH secretagogues may be less likely to induce desensitization and unwanted side-effects such as those related to the extended (10-12 hour or greater) plasma life of exogenous rHGH. Cellular (receptor) desensitization to GH is more likely to occur with a longer, shallower pulse like that found in rHGH.
Somatopause, or diminished GH release due to age, does not result from inability to produce GH but rather due to a reduction in signaling. The pituitary of most older humans can still produce the same amount of GH with the same frequency, but diminished activity of signaling compounds ghrelin and endogenous GHRH create a reduction in GH release relative to younger persons.
 Frohman, L.A., Downs, T.R. and Chomczynski, P. (1992) Regulation of growth hormone secretion. Front. Neuroendocrinol. 13, 344–40
 Chen, C., Wu, D. and Clarke, I.J. (1996) Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J. Endocrinol. 148, 381–386
 Bercu, B.B., Yang, S-W., Masuda, R. and Walker, R.F. (1992) Role of selected endogenous peptides in growth hormone releasing hexapeptide (GHRP) activity: analysis of GHRH, TRH and GnRH. Endocrinology 130, 2579–2586.
 Bowers CY, Momany F, Reynolds GA. In vitro and in vivo activity of a small synthetic peptide with potent GH releasing activity. 64th Annual Meeting of the Endocrine Society, San Francisco, 1982, p. 205
Bowers CY, Momany F, Reynolds GA, Sartor O. Multiple receptors mediate GH release. 7th International Congress of Endocrinology, Quebec, Canada, 1984, p. 464.